Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006379 · ClinicalTrials.gov registry record · Phase 2
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00006379 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 58 participants.
The verdict
NCT00006379, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating patients who have hematologic cancer or aplastic anemia.
Interventions
- DRUG cyclophosphamide
- DRUG fludarabine phosphate
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL graft-versus-tumor induction therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2000-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006379
The ClinicalTrials.gov registry entry for NCT00006379 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00006379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006379 about?
NCT00006379 is a clinical study titled "Non-Ablative Allo HSCT For Hematologic Malignancies or SAA". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. PURPOSE: Phase II trial to study the effec...
What is the current status of trial NCT00006379?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2000-06. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00006379?
The interventions under investigation include: cyclophosphamide (DRUG), fludarabine phosphate (DRUG), peripheral blood stem cell transplantation (PROCEDURE), anti-thymocyte globulin (BIOLOGICAL), graft-versus-tumor induction therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006379?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.